Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium augmentation in escitalopram-treated patients with major depression
2008-004182-26Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of escitalopram and lithium carbonate in major depressive disorder (MDD), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Antidepressive efficacy, Safety and 1 more. Started Feb 2009; status: completed.
02
Drugs
escitalopramlithium carbonate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-004182-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004182-26.